BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Business > article

Samsung BioLogics files administrative suit against financial regulators

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : November 28, 2018, 09:12 | Updated : November 28, 2018, 09:12
  • 트위터
  • 페이스북
  • 웨이보

[Yonhap News Photo]


SEOUL -- Samsung BioLogics launched a legal battle against a decision by financial regulators that the crucial biosimilar arm of South Korea's largest Samsung Group violated accounting rules in 2015 to inflate profits ahead of its listing.

BioLogics said Wednesday that it has sent an application for an administrative litigation and the suspension of execution to a court in Seoul, two weeks after the Securities and Futures Commission imposed a fine of eight billion won ($7.07 million) and recommended the sacking of its chief executive.

The commission asked prosecutors to open a criminal investigation, and South Korea's securities exchange suspended BioLogics to determine whether it should be delisted. BioLogics said the suspension of execution would minimize confusion among investors and prevent possible damage.

The commission said BioLogics suddenly changed a subsidiary into a related company, although it has no reason to change its judgment. BioLogics has denied any accounting fraud, insisting it adopted international standards through consultations with outside experts when it was listed on the local bourse in 2016. At that time, the company reported a net profit of 1.9 trillion won after staying in the red for four years.

Through its public offering, BioLogics raised some 2.25 trillion won, drawing widespread market attention because it's part of efforts by Samsung Electronics vice chairman Jay Y. Lee to realign the parent group's business portfolio.

In 2012, BioLogics set up Samsung Bioepis, a joint venture with U.S.-based pharmaceutical company Biogen. This month, the American partner increased its stake to one share short of 50 percent. Bioepis is known for Imraldi, an adalimumab biosimilar referencing Humira.

The dispute began in May when financial regulators disclosed information on their provisional decision that BioLogics breached accounting rules, leading to a fall in the share prices of BioLogics.

Bioepsis had been valued at market prices instead of its book value. By applying different accounting rules, its value surged from 290 billion won to 4.8 trillion won. BioLogics said a different accounting system was applied because the possibility of Biogen exercising its call option increased. In July, the Financial Services Commission, a powerful financial watchdog, ruled that BioLogics left out important information intentionally about a call option deal with Biogen.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Samsung Bioepis forges licensing deal with Chinese private equity firm .
    Samsung Bioepis forges licensing deal with Chinese private e…
  • .Samsung Bioepis wins U.S. approval to sell cancer-treating biosimilar .
    Samsung Bioepis wins U.S. approval to sell cancer-treating b…
  • .Samsung Bioepis partners with 3SBio to commercialize biosimilar candidates in China.
    Samsung Bioepis partners with 3SBio to commercialize biosimi…
  • .New drug for neutropenia seeks FDA sanction.
    New drug for neutropenia seeks FDA sanction
  • .Financial regulators accuse Samsung BioLogics of breaching accounting rules.
    Financial regulators accuse Samsung BioLogics of breaching a…

Real Time Photo News

  • .Girl band AOAs Seolhyun stars in cable TVs historical period drama .

    Girl band AOA's Seolhyun stars in cable TV's historical period drama

  • .BTS becomes first K-pop band to go on global stadium tour.

    BTS becomes first K-pop band to go on global stadium tour

  • .Rookie girl band ITZY drops dance practice video for debut song.

    Rookie girl band ITZY drops dance practice video for debut song

  • .S.E.S. member Shoo gets suspended jail term for habitual gambling.

    S.E.S. member Shoo gets suspended jail term for habitual gambling

  • .Girl band TWICE to come back in April with new album.

    Girl band TWICE to come back in April with new album

Latest News

more+

  • Purported CG images of Samsung's first foldable phone leaks online
  • SK Telecom forges partnership with Microsoft to roll out cloud-based big data analytics service
  • S. Korea ready to set up inter-Korean fishing zone along sea border
  • Girl band AOA's Seolhyun stars in cable TV's historical period drama
  • BTS becomes first K-pop band to go on global stadium tour
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view